Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01093 CSPC PHARMA
RTNominal up6.520 +0.300 (+4.823%)
Others

17/11/2017 09:40

[I-bank focus]UOBKH lifts CSPC Pharma (01093) to HK$20.1

[ET Net News Agency, 17 November 2017] UOB Kay Hian lifted its target price for CSPC
Pharmaceutical (01093) to HK$20.1 from HK$15.24, and maintained its "buy" rating.
The research house expects CSPC's strong growth momentum to continue in 4Q and 2018,
driven by an enhanced sales network and launch of the new NRDL, NBP injections and
Jinyouli maintained resilient sales growth in 3Q.
It noted that CSPC will launch two blockbuster drugs in 1Q 2018, Albumin-bound
paclitaxel and Clopidogrel. Meanwhile, due to stringent environment regulations, the high
prices of Vitamin C are likely to be maintained in 2018.
UOBKH revised up its 2018/19 earnings estimates by 2.9% and 3.9%. (KL)

Back to Others

Remark: Real time quote last updated: 25/04/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.